Search

Displaying results 3501 - 3510 of 9705 in total
  1. Drug

    Pipequaline

    go.drugbank.com/drugs/DB13991
    Experimental

    However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic or anticonvulsant effect. … Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.

  2. Drug

    AZD-7325

    go.drugbank.com/drugs/DB13994
    Investigational

    AZD7325 is a high affinity, selective modulator of the GABAA receptor system. [L2936]

  3. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life [L2346].

  4. Drug

    SR-9009

    go.drugbank.com/drugs/DB14013
    Experimental

    SR-9009 is a REV-ERB agonist.

  5. Drug

    Sodium bisulfite

    go.drugbank.com/drugs/DB14015
    ApprovedWithdrawn

    Sodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Furafylline

    go.drugbank.com/drugs/DB14029
    Experimental

    Furafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for [theophylline].

  7. Drug

    PZM21

    go.drugbank.com/drugs/DB14030
    Experimental

    PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands

  8. Drug

    Acetyl sulfisoxazole

    go.drugbank.com/drugs/DB14033
    ApprovedVet approved

    Sulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity.

  9. Drug

    Erenumab

    go.drugbank.com/drugs/DB14039
    ApprovedInvestigational

    Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines … CGRP receptor, which is believed to play a critical role in migraine [L2823].

    Products: Pasurta 70mg/ml Solution for Injection in a Prefilled Syringe
  10. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals.